Playback speed
10 seconds
Durvalumab (Imfinzi) FDA Approved for Stage III NSCLC: Standard of Care?
By
Beacon Medical Interchange
FEATURING
Jack West
By
Beacon Medical Interchange
FEATURING
Jack West
20 views
November 2, 2018
Dr. Jack West reviews key results of the PACIFIC trial of the immunotherapy agent durvalumab ...
read more ↘ (Imfinzi) vs. placebo in stage III NSCLC and explains the pros and cons of durvalumab as a new standard of care after concurrent chemoradiation.
↖ read less
read more ↘ (Imfinzi) vs. placebo in stage III NSCLC and explains the pros and cons of durvalumab as a new standard of care after concurrent chemoradiation.
↖ read less
Comments 0
Login to view comments.
Click here to Login
Lung